Phase Ib trial with dose expansion of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in patients with refractory/recurrent primary central nervous system lymphoma (PCNSL) and refractory/recurrent secondary central nervous system lymphoma (SCNSL) Meeting Abstract

  

Authors:	Grommes, C.; Piotrowski, A.; Pentsova, E.; Nolan, C.; Francis, J.; DeAngelis, L.; Schaff, L.; Mellinghoff, I. K.
Abstract Title:	Phase Ib trial with dose expansion of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in patients with refractory/recurrent primary central nervous system lymphoma (PCNSL) and refractory/recurrent secondary central nervous system lymphoma (SCNSL)
Meeting Title:	62nd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	136
Issue:	Suppl. 1
Meeting Dates:	2020 Dec 5-8
Meeting Location:	Virtual
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2020-11-05
Language:	English
ACCESSION:	WOS:000607205606076
DOI:	10.1182/blood-2020-143075
PROVIDER:	wos
Notes:	Meeting Abstract: 48 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/197760